Ferroptosis: Iron, Lipid Peroxidation, Glutathione, And Cell Death

Ferroptosis is an iron-dependent form of regulated cell death in which lipid peroxidation overwhelms the cell's membrane-protection systems. R

In this post, we will discuss how ferroptosis works, why GPX4, system Xc−, glutathione, selenium, iron, and polyunsaturated fats matter, how the pathway differs in cancer and degenerative disease, and how to think about a practical safety-first protocol.

---

What Is Ferroptosis

Ferroptosis is an iron-dependent form of Regulated Cell Death (RCD) driven by the accumulation of oxidized membrane lipids. R

The term was introduced in 2012 after researchers showed that a small molecule called erastin caused a distinct, iron-dependent, nonapoptotic death process in certain cancer cells. R

Ferroptosis is different from apoptosis because it is organized around redox collapse and membrane lipid damage rather than caspase-dependent dismantling of the cell. R

It is different from ordinary necrosis because ferroptosis has identifiable metabolic control points that can be blocked by iron chelation or lipid radical-trapping compounds in experimental models. R

The central failure is not simply that a cell contains too much iron.

The central failure is that iron-catalyzed lipid oxidation exceeds the capacity of glutathione peroxidase 4 and parallel antioxidant systems to stop the chain reaction. R

Ferroptosis is therefore best understood as a threshold event.

Cells can tolerate some iron, oxygen, and lipid oxidation because they continuously repair or remove oxidized lipids.

When iron availability rises, vulnerable phospholipids accumulate, and lipid-peroxide repair fails at the same time, the membrane crosses a point from manageable oxidative stress into self-propagating damage. R

The same pathway can be useful when it selectively removes a cancer cell and harmful when it kills a neuron, kidney cell, cardiomyocyte, or intestinal epithelial cell. R

That context dependence is the reason indiscriminate ferroptosis suppression or induction can backfire.

The Iron, Lipid, And Redox Triangle

Iron

Iron is required for oxygen transport, electron transfer, heme synthesis, and many enzymes, so the goal is not to eliminate iron. R

The relevant pool for ferroptosis is the Labile Iron Pool (LIP), which contains redox-active iron that can participate in reactions generating lipid-damaging radicals. R

Iron enters cells through Transferrin Receptor 1 (TfR1), is stored inside ferritin, and exits through Ferroportin (FPN1), creating several control points before free iron can catalyze membrane oxidation. R

Nuclear Receptor Coactivator 4 (NCOA4) can deliver ferritin to lysosomes for degradation in a process called ferritinophagy, releasing stored iron and sometimes increasing ferroptosis sensitivity. R

Iron overload can therefore increase vulnerability, but a high total-body iron measurement would not by itself prove that ferroptosis is occurring in a particular tissue.

The iron signal has to be interpreted alongside lipid oxidation, antioxidant capacity, cell type, and disease context.

Polyunsaturated Fatty Acids

Polyunsaturated Fatty Acids (PUFAs) are vulnerable to oxidation because their multiple double bonds make hydrogen abstraction and radical propagation easier than in saturated or monounsaturated fats. R

Ferroptosis is especially sensitive to the composition of PUFA-containing phospholipids in cellular membranes.

Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) activates long-chain fatty acids and enriches membranes with PUFA species that make cells more susceptible to ferroptosis. R

Lysophosphatidylcholine Acyltransferase 3 (LPCAT3) helps incorporate activated PUFAs into phospholipids, creating substrates that can be oxidized during ferroptosis. R

The important distinction is that PUFAs are not automatically harmful.

PUFAs are necessary for membrane structure, signaling, and normal physiology, and the effect of a given fatty acid depends on its location, degree of oxidation, membrane remodeling, and the cell's antioxidant defenses. R

I do not recommend trying to eliminate all PUFAs as a ferroptosis strategy.

The more defensible target is preventing excessive oxidation while preserving normal membrane biology.

Lipid Peroxidation

Lipid Peroxidation is a chain reaction in which a lipid radical reacts with oxygen, forms a lipid peroxyl radical, and propagates oxidation through neighboring membrane lipids. R

Iron can convert lipid hydroperoxides into more reactive radical species, allowing the reaction to accelerate rather than remain a low-level background process. R

The final injury is not just a higher oxidative-stress number.

The membrane becomes chemically altered, ion gradients become unstable, membrane proteins lose their environment, and the cell can no longer maintain its normal barrier and signaling functions. R

The GPX4 And Glutathione Defense System

System Xc−

Cystine/Glutamate Antiporter System Xc− is a membrane transporter composed mainly of SLC7A11 and SLC3A2 that imports cystine in exchange for glutamate. R

Cystine is reduced to cysteine inside the cell, and cysteine is one of the required building blocks for Glutathione (GSH) synthesis. R

Blocking system Xc− reduces cystine availability, lowers GSH production, and weakens the cell's ability to keep GPX4 active. R

This is why erastin, a laboratory ferroptosis inducer, was able to trigger oxidative cell death by interfering with cystine uptake rather than by directly poisoning the membrane. R

Glutathione

GSH is the major intracellular thiol antioxidant used by GPX4 to reduce lipid hydroperoxides into less reactive lipid alcohols. R

GSH is synthesized from glutamate, cysteine, and glycine through the actions of glutamate-cysteine ligase and glutathione synthetase. R

After GPX4 uses reduced GSH, the resulting oxidized glutathione can be recycled by glutathione reductase using reducing equivalents from NADPH. R

GSH depletion is therefore not an isolated nutrient problem.

It can reflect insufficient cystine transport, inadequate amino-acid supply, high oxidative demand, impaired NADPH regeneration, increased detoxification demand, or inflammatory signaling that changes redox metabolism. R

GPX4

Glutathione Peroxidase 4 (GPX4) is the enzyme that directly reduces phospholipid hydroperoxides inside membranes. R

GPX4 is the most important single brake on ferroptosis identified to date, but it is not the only one. R

When GPX4 is inhibited, depleted, or overwhelmed, lipid peroxides accumulate and ferroptosis can follow if iron and susceptible phospholipids are available. R

Selenium is required for the selenocysteine-containing form of GPX4, and experimental work shows that selenium utilization makes GPX4 more resistant to irreversible peroxide-induced inactivation. R

That result does not mean that high-dose selenium is a universal ferroptosis treatment.

It means that adequate selenium status is one of the prerequisites for normal GPX4 biology.

Backup Defenses

Cells have additional ferroptosis defenses that can compensate partially when the GSH-GPX4 axis is stressed.

Ferroptosis Suppressor Protein 1 (FSP1) uses NAD(P)H to regenerate reduced CoQ10 at the plasma membrane, where reduced CoQ10 can trap lipid radicals in experimental systems. R

GTP Cyclohydrolase 1 (GCH1) generates Tetrahydrobiopterin (BH4), which can remodel membrane lipids and support a radical-trapping defense that is independent of GPX4 in cell models. R

Mitochondrial Dihydroorotate Dehydrogenase (DHODH) can also use reduced CoQ10 to protect mitochondrial membranes from lipid peroxidation, especially in cells with low GPX4 activity in preclinical models. R

Vitamin E, CoQ10, vitamin K, BH4, and related lipid-soluble molecules can act as radical-trapping antioxidants in experimental systems. R

The presence of several backup systems is another reason why a single blood measurement cannot diagnose ferroptosis.

Ferroptosis And Cancer

Ferroptosis is attractive in oncology because many cancer cells evade apoptosis, while some remain dependent on iron metabolism, PUFA remodeling, and GPX4-mediated lipid-peroxide control. R

The pathway is particularly interesting in therapy-resistant cancer cells that survive by increasing antioxidant defenses or changing their lipid composition. R

Laboratory ferroptosis inducers include system Xc− inhibitors, GPX4 inhibitors, iron-handling modulators, and compounds that increase oxidizable membrane lipids. R

Some cancer immunotherapies can increase ferroptosis pressure through interferon-gamma signaling, which can suppress system Xc− activity and increase tumor-cell lipid vulnerability in mechanistic and preclinical studies. R

This creates a plausible connection between ferroptosis and immune checkpoint therapy, but it does not mean that taking an over-the-counter antioxidant or iron product can reproduce an oncology protocol.

The tumor must be sensitive, the drug must reach the tumor, the ferroptosis defense network must be understood, and normal tissues must be protected.

The translational gap is large.

A 2025 review concluded that dedicated ferroptosis therapies had not yet entered clinical testing as a defined therapeutic class, despite extensive preclinical work. R

This is where indiscriminate ferroptosis induction can backfire.

A drug that raises lipid peroxidation in a tumor may also injure neurons, kidney tissue, liver tissue, blood vessels, or immune cells if it lacks selectivity.

Conversely, a large antioxidant stack could theoretically reduce the oxidative pressure that an oncology treatment is trying to create, although the clinical effect depends on the specific treatment and cannot be predicted from ferroptosis theory alone.

Anyone with active cancer should treat ferroptosis modulation as an oncology question, not as a supplement experiment.

Ferroptosis And Degenerative Disease

The disease context reverses the therapeutic logic.

In a neuron or kidney cell, the desired outcome is usually to preserve GPX4 activity, control iron-driven lipid oxidation, and prevent membrane damage rather than to induce ferroptosis.

Neurodegeneration

Iron accumulation, lipid peroxidation, reduced GSH, and impaired GPX4 signaling have all been reported in Alzheimer disease research, but the evidence does not prove that ferroptosis is the single cause of neuronal loss. R

Iron dysregulation has also been associated with Parkinson disease, Alzheimer disease, and amyotrophic lateral sclerosis, while the exact link between regional iron and neuron death remains incompletely defined. R

Most therapeutic evidence in neurodegeneration remains cell-based or animal-based, including studies using ferrostatin-1, liproxstatin-1, iron chelators, NRF2 activation, or GPX4-supportive strategies. R

The human evidence is not strong enough to justify self-diagnosing neurodegenerative disease as ferroptosis or taking an iron chelator without a medical indication.

Ischemia And Reperfusion

Ferroptosis has been implicated in ischemia-reperfusion injury, stroke, kidney injury, liver injury, and cardiovascular disease. R

The mechanism is biologically plausible because oxygen deprivation, iron release, mitochondrial stress, and sudden reoxygenation can converge on lipid-peroxide accumulation. R

The strongest protective studies in these conditions are generally preclinical, so a compound that blocks ferroptosis in a mouse model should not be assumed to improve outcomes in a human emergency. R

Inflammation And Chronic Illness

Oxidized lipids can act as inflammatory signals, and inflammatory cytokines can alter iron handling, cystine transport, lipid remodeling, and antioxidant gene expression. R

This creates a feedback loop in which inflammation lowers the cell's reserve against lipid oxidation, while oxidized membranes amplify inflammatory signaling.

In Jacob's hypothesis, Junction Dysfunction can create a tissue environment with hypoxia, inflammatory signaling, mitochondrial stress, and impaired redox reserve that may make ferroptotic injury easier to trigger.

That is a hypothesis about susceptibility, not a claim that every symptom attributed to Junction Dysfunction is ferroptosis.

I am also not presenting ferroptosis as a replacement for the clinical evaluation of anemia, iron overload, infection, medication toxicity, ischemia, cancer, or neurodegenerative disease.

Ferroptosis And Junction Dysfunction

Jacob's framework treats Junction Dysfunction (JD) as a multifactorial loss of glycocalyx integrity that can include Transient Capillary Leak Syndrome (TCLS), Micro-Sepsis (MSS), hypoxia, and impaired Vaso-Adaptation.

Jacob coined the terms TCLS and MSS for the framework's microvascular and sub-lethal inflammatory components.

The overlap with ferroptosis is mechanistic rather than diagnostic.

Hypoxia can alter mitochondrial metabolism, inflammatory signaling can change iron and lipid handling, and oxidative stress can reduce the margin of safety between normal lipid turnover and membrane damage. R

Jacob's hypothesis is that ferroptosis may be one downstream injury mode inside this larger adaptive-system failure, especially in tissues already struggling with oxygen delivery and redox recovery.

The practical implication is to restore reserve and identify the driver rather than reflexively suppressing every reactive oxygen species or attempting to induce cell death.

I do not teach the proprietary JD cascades in this article because ferroptosis is a mainstream cell-death pathway with its own evidence base, and the two frameworks should not be treated as interchangeable.

How To Improve Ferroptosis Balance

There is no validated consumer protocol that measures ferroptosis and then turns it up or down with precision.

The practical approach is to protect normal cells from avoidable iron-catalyzed lipid damage while preserving the ability to use ferroptosis selectively in specialist cancer treatment.

1. Clarify The Direction Of The Intervention

The first question is whether the clinical goal is to prevent excessive ferroptotic injury or to make a tumor more sensitive to a prescribed therapy.

Those goals are opposite, and a supplement that is reasonable in one context can be counterproductive in the other.

Do not use this article to build a ferroptosis-inducing cancer protocol outside an oncology team.

2. Do Not Add Iron Blindly

Iron is not a generic energy supplement, and additional iron can be harmful when iron stores are already adequate or elevated.

If iron overload is a concern, begin with clinician-led evaluation and use my post on iron overload, ferritin, HFE, and hemochromatosis for the broader context.

If iron deficiency is suspected, the cause matters because blood loss, absorption problems, inflammation, infection, and inherited disorders require different responses.

Do not use an iron supplement to treat fatigue without establishing that iron replacement is indicated.

3. Support The GSH-GPX4 Axis

Adequate protein intake supplies the amino acids required to make GSH, but the exact protein target should be individualized for kidney function, liver function, digestion, age, and medical status.

**N-Acetylcysteine** can provide cysteine for GSH synthesis, but its ability to prevent ferroptosis in a specific human tissue has not been established in clinical trials.

**Glutathione** is mechanistically relevant because GPX4 uses it, and a six-month randomized trial found that oral GSH increased glutathione stores in healthy adults. R

That result does not prove that oral GSH prevents ferroptosis, and a shorter randomized trial in healthy adults found no significant change in oxidative-stress or GSH biomarkers after four weeks. R

I cover the precursor and formulation debate in my post on glutathione benefits, precursors, and forms.

4. Correct Selenium Insufficiency, Do Not Megadose It

**Selenium** is required for selenocysteine-containing GPX4, making adequate intake biologically relevant to ferroptosis defense. R

The evidence for using selenium to treat ferroptosis in humans is not established because the direct GPX4 evidence is primarily mechanistic and preclinical. R R

Selenium supplementation makes the most sense when dietary intake is low, deficiency is documented or strongly suspected, or a clinician has a specific reason to use it.

Excess selenium can cause hair and nail changes, gastrointestinal symptoms, and other toxic effects, and a European Food Safety Authority review set a tolerable upper intake level of 255 micrograms per day for adults. R

I discuss the broader thyroid and immune context in my post on selenium benefits.

5. Protect Membrane Lipids Without Removing All PUFAs

**Vitamin E** can trap lipid radicals and participates in the broader network that limits membrane peroxidation. R

I prefer food sources and moderate, context-specific supplementation over chronic high-dose vitamin E because antioxidant effects do not become safer just because the target is oxidative stress.

I discuss the different tocopherol forms in my post on tocopherols and vitamin E.

High-dose vitamin E has a mixed clinical risk-benefit profile, and supplementation should be reviewed when there is bleeding risk, anticoagulant use, surgery, or active cancer treatment. R

The practical goal is to reduce the repeated exposure of membranes to already-oxidized fats while keeping adequate essential fatty acids in the diet.

Do not treat all omega-3 or omega-6 intake as a ferroptosis problem because membrane context, oxidation status, and cellular remodeling determine susceptibility. R

6. Preserve The Backup Systems

**Coenzyme Q10** is part of the FSP1-CoQ10 defense network that can trap lipid radicals in experimental models. R

This does not mean that CoQ10 supplementation has been proven to prevent human ferroptosis.

It means that mitochondrial and membrane redox systems are connected, so a protocol should not focus on GSH while ignoring energy production, NADPH recycling, mitochondrial disease, medication effects, sleep, or ongoing inflammation.

7. Treat The Driver

Iron overload, iron deficiency, chronic inflammation, ischemia, renal disease, liver disease, toxin exposure, cancer therapy, and neurodegenerative disease can all change the ferroptosis balance through different mechanisms. R

The best protocol is therefore cause-specific.

A person with iron overload should not follow the same plan as a person with iron deficiency, and a person receiving chemotherapy should not follow the same antioxidant plan as a person recovering from ischemic injury.

What To Stay Away From

Blind Iron Supplementation

Do not add iron because fatigue feels like low iron.

Iron replacement should follow a documented clinical rationale because excess redox-active iron can increase lipid-peroxide pressure. R

High-Dose Selenium

Do not stack selenium products, Brazil nuts, multivitamins, and thyroid formulas without calculating the total intake.

The GPX4 connection is real, but selenium toxicity is also real. R

High-Dose Antioxidant Stacking During Cancer Treatment

Do not assume that more GSH, vitamin E, NAC, CoQ10, or other antioxidants are automatically helpful during a therapy designed to create oxidative injury in a tumor.

The direction of effect is treatment-specific, and ferroptosis research is actively trying to solve tumor selectivity and normal-tissue toxicity. R

Extreme PUFA Elimination

Do not remove all PUFAs or treat one category of dietary fat as the universal cause of ferroptosis.

Ferroptosis sensitivity depends on membrane remodeling, lipid species, iron availability, and antioxidant capacity rather than on a simple good-fat versus bad-fat rule. R

Self-Diagnosing Ferroptosis From Nonspecific Symptoms

Fatigue, brain fog, pain, weakness, and exercise intolerance are not specific evidence of ferroptosis.

They can result from many conditions that require different evaluations and treatments.

Testing

There is no validated home test or single routine laboratory result that establishes ferroptosis in a living person.

Current research uses combinations of lipid-peroxidation products, iron-handling proteins, gene expression, protein activity, tissue morphology, and rescue with ferroptosis inhibitors, and even these markers have specificity limitations. R

I use the **Cellular Zoomer** to assess organic acids, mitochondrial function, oxidative stress, and methylation-related patterns, but it does not diagnose ferroptosis.

I use the **Nutrient Zoomer** to assess vitamins, minerals, amino acids, and fatty-acid patterns that can influence redox reserve, but it does not identify which tissue is undergoing ferroptosis.

If iron excess is the clinical question, use a clinician-led workup and my iron-overload article for context rather than ordering a ferroptosis panel that has not been clinically validated.

If the concern is neurodegeneration, kidney injury, ischemia, or cancer, test for and treat the underlying disease rather than treating a pathway label as a diagnosis.

The current research limitation is direct human tissue measurement.

A recent review noted that no single marker is sufficient to establish ferroptosis in human Alzheimer disease tissue, which is a useful warning for anyone selling a one-marker explanation. R

Mechanisms Of Action

Simple:

• Iron helps generate the reactive chemistry that starts and accelerates lipid oxidation.
• Lipid membranes become vulnerable when oxidizable PUFA-containing phospholipids accumulate faster than they can be repaired.
• Redox defenses use GSH, GPX4, CoQ10, vitamin E, BH4, and NADPH-linked systems to stop lipid-radical propagation.
• System Xc− imports cystine so the cell can make GSH and keep GPX4 working.

Advanced:

• ACSL4 and LPCAT3 enrich phospholipid membranes with PUFA-containing substrates, while lipoxygenases and other oxidant systems generate phospholipid hydroperoxides that become lethal when repair capacity is exceeded. R R
• FSP1-CoQ10 provides a GPX4-independent plasma-membrane defense by using NAD(P)H to regenerate reduced CoQ10, which traps lipid radicals. R
• GCH1-BH4 counteracts ferroptosis through BH4 production, CoQ10 support, and selective preservation of phospholipids with two PUFA tails. R
• Iron trafficking and ferritinophagy regulate the LIP through TfR1 uptake, ferritin storage, ferroportin export, and NCOA4-mediated ferritin degradation. R
• NADPH metabolism powers glutathione reductase, FSP1, thioredoxin reductases, and other systems that recycle oxidized defenses back into active forms. R
• SLC7A11, glutathione, and GPX4 form the core cystine-redox-peroxide axis, with SLC7A11 supplying cystine, GSH supplying reducing equivalents, and GPX4 reducing phospholipid hydroperoxides. R
• Selenium-dependent GPX4 uses selenocysteine chemistry that is more resistant to irreversible overoxidation than a cysteine-substituted GPX4 variant in experimental systems. R

Genetics

ACSL4

ACSL4 encodes an enzyme that helps activate long-chain fatty acids for incorporation into membrane phospholipids.

Higher ACSL4 activity can increase the abundance of PUFA-containing membrane substrates and ferroptosis sensitivity in cell and tumor models, not establish a human genetic risk estimate. R

ACSL4 expression is a research variable, not a consumer genetic diagnosis of ferroptosis risk.

AIFM2

AIFM2 encodes FSP1, an alternative ferroptosis defense protein that regenerates reduced CoQ10 at the plasma membrane.

The pathway is biologically important, but routine clinical interpretation of AIFM2 variants for ferroptosis susceptibility is not established. R

GPX4

GPX4 encodes the central phospholipid hydroperoxide-reducing enzyme in the GSH-dependent ferroptosis defense system.

A partial loss-of-function GPX4 mutation has been identified in human genetic research, but this is rare biology and not a routine explanation for common fatigue or oxidative-stress symptoms. R

NCOA4

NCOA4 encodes the cargo receptor that mediates ferritinophagy and helps release stored iron when cells need it.

Changes in NCOA4-mediated ferritin turnover can alter the LIP and ferroptosis sensitivity in disease models, but a clinical NCOA4 result does not diagnose tissue ferroptosis. R

NFE2L2

NFE2L2 encodes Nuclear Factor Erythroid 2-Related Factor 2 (NRF2), a transcription factor that activates antioxidant and detoxification genes when cells experience oxidative stress.

NRF2 can protect cells from ferroptosis by increasing redox defenses, although persistent NRF2 activation can also help some cancer cells survive therapy. R

SLC7A11

SLC7A11 encodes the cystine-import component of system Xc− and is a major control point for cysteine availability and GSH synthesis.

Tumors can increase SLC7A11 to resist ferroptosis, while experimental inhibition of SLC7A11 can make susceptible cells more vulnerable to lipid-peroxide accumulation. R

Selenium Biology

The machinery that inserts selenocysteine into GPX4 depends on selenium availability and specialized selenoprotein synthesis pathways.

This is why selenium status can influence GPX4 activity, but it does not justify taking high-dose selenium without considering total intake and toxicity. R R

More Research

• Biomarkers remain unresolved because lipid-peroxidation products, iron changes, GPX4 expression, and ferroptosis-related genes can also change during other forms of oxidative injury. R
• C15:0 is being proposed as a membrane-stability and ferroptosis-related nutrient, but the current argument is preliminary, includes mechanistic and observational evidence, and requires independent clinical trials. R R
• Clinical translation is limited because many ferroptosis studies use cell lines, animal models, or compounds that are not selective enough for human therapy. R
• Immune crosstalk may determine whether ferroptotic tumor cells stimulate antitumor immunity or create an inflammatory and immunosuppressive environment, so ferroptosis cannot be separated from the tumor microenvironment. R
• Mitochondrial defenses involving DHODH, CoQ10, NADPH, and membrane remodeling may explain why two cells with similar GPX4 levels can have different ferroptosis thresholds. R
• Nutrient intervention needs human studies that measure target engagement, tissue-specific lipid oxidation, clinical outcomes, and interactions with medications rather than relying on GSH or oxidative-stress surrogate changes alone. R